Have you ever reviewed a resident’s medications and paused at an antipsychotic? Have you wondered if it is truly necessary? Antipsychotic use in senior care continues to be a complex issue. Providers must balance regulatory expectations with individualized resident needs.
For years, CMS has emphasized reducing unnecessary antipsychotic medications in long-term care. The goal is clear. Improve quality of life and reduce avoidable medication use. However, the reality is not always straightforward. Some residents have clinical conditions where these medications may still play a role. Removing them too quickly or without proper oversight can create additional challenges. Recent reporting on CMS’s review of the nursing home antipsychotic quality measure highlights the dilemma providers face as they try to balance regulatory pressure with appropriate clinical care.
Additional coverage discussing how providers can navigate antipsychotic expectations amid renewed pressure on CMS reinforces just how much uncertainty communities continue to face in this area. CMS has acknowledged that reducing antipsychotic use remains important. It must also consider residents who may legitimately benefit from these medications.
At the same time, CMS guidance outlined in QSO-25-12-NH reinforces expectations around appropriate prescribing, documentation, and ongoing monitoring of antipsychotic medications in nursing homes. The memo says revised surveyor guidance addresses chemical restraints and unnecessary psychotropic medication, and CMS said surveyors began using that guidance on March 24, 2025. This includes making sure each resident’s care plan reflects individualized needs. It also includes attempting gradual dose reductions when appropriate. Non-pharmacological interventions should be considered first whenever possible. CMS also says the guidance now emphasizes the resident’s right to be informed of, participate in, accept, or decline treatment before a psychotropic medication is started or increased.
So, what are providers to do? It starts with strong interdisciplinary collaboration. Nursing, medical providers, pharmacy consultants, and behavioral health professionals all play a role. They help evaluate whether an antipsychotic is appropriate. Documentation also remains critical. Providers should clearly outline the clinical rationale, interventions attempted, and the resident’s ongoing response.
It is also important to remember that surveyors will continue to focus on this area. Communities should ensure policies align with current CMS guidance. Staff should understand both the risks and the expectations tied to antipsychotic use.
At the end of the day, antipsychotic use in senior care is about balance. Providers must weigh regulatory expectations with clinical judgment. They must also keep the resident’s well-being at the center of every decision. Staying informed and proactive can help communities navigate this evolving landscape with confidence.
Stay well and stay informed!
